Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Assisted Reproduction and Genetics
Published in: Journal of Assisted Reproduction and Genetics 10/2018

01-10-2018 | Review

The curious case of premature luteinization

Authors: Apostolos Kaponis, Elpiniki Chronopoulou, George Decavalas

Published in: Journal of Assisted Reproduction and Genetics | Issue 10/2018

Login to get access

Abstract

Purpose

Premature luteinization (PL) affects 12.3–46.7% of fresh in vitro fertilization cycles, and there is accumulating evidence confirming its negative effect on success rates. However, despite its clinical significance, PL is poorly understood and defined. This narrative review aims to provide a fresh look at the phenomenon of PL by summarizing the existing evidence and re-evaluating fundamental issues.

Methods

A thorough electronic search was conducted covering the period from 1978 until January 2018 in PubMed, Embase, and Medline databases, and references of relevant studies were cross-checked. Meeting proceedings of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine were also hand searched.

Results

In the curious case of PL, one should go back to the beginning and re-consider every step of the way. The pathogenesis, definition, measurement methods, clinical implications, and management strategies are discussed in detail, highlighting controversies and offering “food for thought” for future directions.

Conclusions

Authors need to speak the same language when studying PL in order to facilitate comparisons. The terminology, progesterone cut-off, measurement methods and days of measurement should be standardized and globally accepted; otherwise, there can be no scientific dialog. Future research should focus on specific patient profiles that may require a tailored approach. Progesterone measurements throughout the follicular phase possibly depict the progesterone exposure better than an isolated measurement on the day of hCG. Adequately powered randomized controlled trials should confirm which the best prevention and management plan of PL is, before introducing any strategy into clinical practice.
Literature
1.
Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013;19(5):433–57.PubMedCrossRef
2.
Schoolcraft W, Sinton E, Schlenker T, Huynh D, Hamilton F, Meldrum DR. Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate. Fertil Steril. 1991;55(3):563–6.PubMedCrossRef
3.
Seow KM, Lin YH, Hsieh BC, Huang LW, Huang SC, Chen CY, et al. Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle. Gynecol Obstet Investig. 2010;70(1):64–8.CrossRef
4.
5.
Hill MJ, Royster GD, Taneja M, Healy MW, Zarek SM, Christy AY, et al. Does elevated progesterone on day of oocyte maturation play a role in the racial disparities in IVF outcomes? Reprod BioMed Online. 2017;34(2):154–61.PubMedCrossRef
6.
Feldberg D, Goldman GA, Ashkenazi J, Dicker D, Shelef M, Goldman JA. The impact of high progesterone levels in the follicular phase of in vitro fertilization (IVF) cycles: a comparative study. J In Vitro Fert Embryo Transf. 1989;6(1):11–4.PubMedCrossRef
7.
Ben-Nun I, Ghetler Y, Jaffe R, Siegal A, Kaneti H, Fejgin M. Effect of preovulatory progesterone administration on the endometrial maturation and implantation rate after in vitro fertilization and embryo transfer. Fertil Steril. 1990;53(2):276–81.PubMedCrossRef
8.
Edelstein MC, Seltman HJ, Cox BJ, Robinson SM, Shaw RA, Muasher SJ. Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome. Fertil Steril. 1990;54(5):853–7.PubMedCrossRef
9.
10.
Silverberg KM, Burns WN, Olive DL, Riehl RM, Schenken RS. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. J Clin Endocrinol Metab. 1991;73(4):797–803.PubMedCrossRef
11.
Dirnfeld M, Goldman S, Gonen Y, Koifman M, Lissak A, Abramovici H. A modest increase in serum progesterone levels on the day of human chorionic gonadotropin (hCG) administration may influence pregnancy rate and pregnancy loss in in vitro fertilization-embryo transfer (IVF-ET) patients. J Assist Reprod Genet. 1993;10(2):126–9.PubMedCrossRef
12.
Legro RS, Ary BA, Paulson RJ, Stanczyk FZ, Sauer MV. Premature luteinization as detected by elevated serum progesterone is associated with a higher pregnancy rate in donor oocyte in-vitro fertilization. Hum Reprod. 1993;8(9):1506–11.PubMedCrossRef
13.
Huang JC, Jackson KV, Hornstein MD, Ginsburg ES. The effect of elevated serum progesterone during ovulation induction in in vitro fertilization-embryo transfer. J Assist Reprod Genet. 1996;13(8):617–24.PubMedCrossRef
14.
Fanchin R, Righini C, Olivennes F, de Ziegler D, Selva J, Frydman R. Premature progesterone elevation does not alter oocyte quality in in vitro fertilization. Fertil Steril. 1996;65(6):1178–83.PubMedCrossRef
15.
Kolibianakis EM, Zikopoulos K, Smitz J, Camus M, Tournaye H, Van Steirteghem AC, et al. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod. 2004;19(7):1525–9.PubMedCrossRef
16.
17.
18.
Xu B, Li Z, Zhang H, Jin L, Li Y, Ai J, et al. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles. Fertil Steril. 2012;97(6):1321–7.PubMedCrossRef
19.
Check JH, Amui J, Choe JK, Brasile D. Relationship of serum progesterone (P) level the day after human chorionic gonadotropin (hCG) injection on outcome following in vitro fertilization-embryo transfer (IVF-ET). Clin Exp Obstet Gynecol. 2009;36(4):214–5.PubMed
20.
Saleh HA, Omran MS, Draz M. Does subtle progesterone rise on the day of HCG affect pregnancy rate in long agonist ICSI cycles? J Assist Reprod Genet. 2009;26(5):239–42.PubMedPubMedCentralCrossRef
21.
Wu Z, Li R, Ma Y, Deng B, Zhang X, Meng Y, et al. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles. Reprod BioMed Online. 2012;24(5):511–20.PubMedCrossRef
22.
Griesinger G, Mannaerts B, Andersen CY, Witjes H, Kolibianakis EM, Gordon K. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril. 2013;100(6):1622–8.PubMedCrossRef
23.
Hamdine O, Macklon NS, Eijkemans MJ, Laven JS, Cohlen BJ, Verhoeff A, et al. Elevated early follicular progesterone levels and in vitro fertilization outcomes: a prospective intervention study and meta-analysis. Fertil Steril. 2014;102(2):448–54.PubMedCrossRef
24.
Cui N, Zhang J, Xu Y, Jiang L, Yang A, Hao G. Premature progesterone rise positively correlates with clinical pregnancy rate in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) patients with good ovarian response. Horm Metab Res. 2017;49(5):372–9.PubMedCrossRef
25.
Ubaldi F, Smitz J, Wisanto A, Joris H, Schiettecatte J, Derde MP, et al. Oocyte and embryo quality as well as pregnancy rate in intracytoplasmic sperm injection are not affected by high follicular phase serum progesterone. Hum Reprod. 1995;10(12):3091–6.PubMedCrossRef
26.
Yovel I, Yaron Y, Amit A, Peyser MR, David MP, Kogosowski A, et al. High progesterone levels adversely affect embryo quality and pregnancy rates in in vitro fertilization and oocyte donation programs. Fertil Steril. 1995;64(1):128–31.PubMed
27.
Niu Z, Feng Y, Zhang A, Sun Y, Zhang H. Progesterone levels on oocyte retrieval day can predict the quantity of viable embryos but not pregnancy outcome of intracytoplasmic sperm injection. Gynecol Endocrinol. 2008;24(8):452–8.PubMedCrossRef
28.
29.
30.
Fanchin R, de Ziegler D, Taieb J, Hazout A, Frydman R. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil Steril. 1993;59(5):1090–4.PubMedCrossRef
31.
Check JH, Hourani C, Choe JK, Callan C, Adelson HG. Pregnancy rates in donors versus recipients according to the serum progesterone level at the time of human chorionic gonadotropin in a shared oocyte program. Fertil Steril. 1994;61(2):262–4.PubMedCrossRef
32.
Shulman A, Ghetler Y, Beyth Y, Ben-Nun I. The significance of an early (premature) rise of plasma progesterone in in vitro fertilization cycles induced by a “long protocol” of gonadotropin releasing hormone analogue and human menopausal gonadotropins. J Assist Reprod Genet. 1996;13(3):207–11. https://​doi.​org/​10.​1007/​bf02065937.CrossRefPubMed
33.
Chetkowski RJ, Kiltz RJ, Salyer WR. In premature luteinization, progesterone induces secretory transformation of the endometrium without impairment of embryo viability. Fertil Steril. 1997;68(2):292–7.PubMedCrossRef
34.
Labarta E, Martinez-Conejero JA, Alama P, Horcajadas JA, Pellicer A, Simon C, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011;26(7):1813–25.PubMedCrossRef
35.
36.
Haouzi D, Bissonnette L, Gala A, Assou S, Entezami F, Perrochia H, et al. Endometrial receptivity profile in patients with premature progesterone elevation on the day of HCG administration. Biomed Res Int. 2014;951937(10):28.
37.
Liu L, Sailan S, Li T, Mariee N, Laird S, Jiang Z, et al. The effect of a high progesterone concentration before oocyte retrieval on the peri-implantation endometrium. Reprod BioMed Online. 2015;31(6):739–46.PubMedCrossRef
38.
Xiong Y, Wang J, Liu L, Chen X, Xu H, Li TC, et al. Effects of high progesterone level on the day of human chorionic gonadotrophin administration in in vitro fertilization cycles on epigenetic modification of endometrium in the peri-implantation period. Fertil Steril. 2017;108(2):269–76.PubMedCrossRef
39.
Shechter A, Lunenfeld E, Potashnik G, Glezerman M. The significance of serum progesterone levels on the day of hCG administration on IVF pregnancy rates. Gynecol Endocrinol. 1994;8(2):89–94.PubMedCrossRef
40.
Harada T, Katagiri C, Takao N, Toda T, Mio Y, Terakawa N. Altering the timing of human chorionic gonadotropin injection according to serum progesterone (P) concentrations improves embryo quality in cycles with subtle P rise. Fertil Steril. 1996;65(3):594–7.PubMedCrossRef
41.
Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzis BC, Tournaye H, Devroey P. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. Fertil Steril. 2011;96(5):1112–5.PubMedCrossRef
42.
43.
Ibrahim Y, Haviland MJ, Hacker MR, Penzias AS, Thornton KL, Sakkas D. Elevated progesterone and its impact on birth weight after fresh embryo transfers. J Assist Reprod Genet. 2017;34(6):759–64.PubMedPubMedCentralCrossRef
44.
Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet. 1978;2(8085):366.PubMedCrossRef
45.
46.
Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis. Hum Reprod Update. 2007;13(4):343–55. https://​doi.​org/​10.​1093/​humupd/​dmm007.CrossRefPubMed
47.
48.
Fleming R, Jenkins J. The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reprod BioMed Online. 2010;21(4):446–9.PubMedCrossRef
49.
Sonigo C, Dray G, Roche C, Cedrin-Durnerin I, Hugues JN. Impact of high serum progesterone during the late follicular phase on IVF outcome. Reprod BioMed Online. 2014;29(2):177–86.PubMedCrossRef
50.
Park JH, Jee BC, Kim SH. Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles. Clin Exp Reprod Med. 2015;42(2):67–71.PubMedPubMedCentralCrossRef
51.
Castillo JL, Bousamra M, Fuente Lde L, Ruiz-Balda JA, Palomo M. The impact of serum progesterone levels on the results of in vitro fertilization treatments: a literature review. JBRA Assist Reprod. 2015;19(3):141–7.PubMedCrossRef
52.
Huang Y, Wang EY, Du QY, Xiong YJ, Guo XY, Yu YP, et al. Progesterone elevation on the day of human chorionic gonadotropin administration adversely affects the outcome of IVF with transferred embryos at different developmental stages. Reprod Biol Endocrinol. 2015;13(82):015–0075.
53.
Mutlu MF, Erdem M, Mutlu I, Bulut B, Erdem A. Elevated basal progesterone levels are associated with increased preovulatory progesterone rise but not with higher pregnancy rates in ICSI cycles with GnRH antagonists. Eur J Obstet Gynecol Reprod Biol. 2017;216:46–50.PubMedCrossRef
54.
Mannaerts B, Devroey P, Åbyholm T, Coelingh H. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod. 1998;13(11):3023–31.CrossRef
55.
Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, et al. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod. 2000;15(11):2333–40.PubMedCrossRef
56.
Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod. 2007;22(11):2805–13.PubMedCrossRef
57.
Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560–79.PubMedCrossRef
58.
Hugues JN, Masse-Laroche E, Reboul-Marty J, Boiko O, Meynant C, Cedrin-Durnerin I. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration. Fertil Steril. 2011;96(3):600–4.PubMedCrossRef
59.
60.
Papanikolaou EG, Pados G, Grimbizis G, Bili E, Kyriazi L, Polyzos NP, et al. GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Hum Reprod. 2012;27(6):1822–8.PubMedCrossRef
61.
Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003;1
62.
63.
Smitz J, Andersen AN, Devroey P, Arce JC. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22(3):676–87.PubMedCrossRef
64.
Hugues JN. Impact of ‘LH activity’ supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review. Hum Reprod. 2012;27(1):232–43.PubMedCrossRef
65.
Hofmann GE, Bentzien F, Bergh PA, Garrisi GJ, Williams MC, Guzman I, et al. Premature luteinization in controlled ovarian hyperstimulation has no adverse effect on oocyte and embryo quality. Fertil Steril. 1993;60(4):675–9.PubMedCrossRef
66.
Thuesen LL, Smitz J, Loft A, Nyboe Andersen A. Endocrine effects of hCG supplementation to recombinant FSH throughout controlled ovarian stimulation for IVF: a dose-response study. Clin Endocrinol. 2013;79(5):708–15.
67.
Copperman AB, Horowitz GM, Kaplan P, Scott RT, Navot D, Hofmann GE. Relationship between circulating human chorionic gonadotropin levels and premature luteinization in cycles of controlled ovarian hyperstimulation. Fertil Steril. 1995;63(6):1267–71.PubMedCrossRef
68.
Adonakis G, Deshpande N, Yates RW, Fleming R. Luteinizing hormone increases estradiol secretion but has no effect on progesterone concentrations in the late follicular phase of in vitro fertilization cycles in women treated with gonadotropin-releasing hormone agonist and follicle-stimulating hormone. Fertil Steril. 1998;69(3):450–3. https://​doi.​org/​10.​1016/​s0015-0282(97)00559-1.CrossRefPubMed
69.
Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update. 2002;8(6):543–57.PubMedCrossRef
70.
Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril. 2005;83(2):309–15.PubMedCrossRef
71.
Andersen CY, Westergaard LG, van Wely M. FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect? Reprod Biomed Online. 2004;9(2):231–6.PubMedCrossRef
72.
Lawrenz B, Beligotti F, Engelmann N, Gates D, Fatemi HM. Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles. Hum Reprod. 2016;31(11):2554–60.PubMedCrossRef
73.
Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update. 2009;15(3):309–21.PubMedCrossRef
74.
75.
76.
Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Jenkins J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010;25(8):2092–100.PubMedCrossRef
77.
Ubaldi F, Camus M, Smitz J, Bennink HC, Van Steirteghem A, Devroey P. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH. Fertil Steril. 1996;66(2):275–80.PubMedCrossRef
78.
Kyrou D, Al-Azemi M, Papanikolaou EG, Donoso P, Tziomalos K, Devroey P, et al. The relationship of premature progesterone rise with serum estradiol levels and number of follicles in GnRH antagonist/recombinant FSH-stimulated cycles. Eur J Obstet Gynecol Reprod Biol. 2012;162(2):165–8.PubMedCrossRef
79.
Smyth CD, Miro F, Whitelaw PF, Howles CM, Hillier SG. Ovarian thecal/interstitial androgen synthesis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism. Endocrinology. 1993;133(4):1532–8.PubMedCrossRef
80.
Campbell BK, Baird DT. Inhibin a is a follicle stimulating hormone-responsive marker of granulosa cell differentiation, which has both autocrine and paracrine actions in sheep. J Endocrinol. 2001;169(2):333–45.PubMedCrossRef
81.
Fournet N, Weitsman SR, Zachow RJ, Magoffin DA. Transforming growth factor-beta inhibits ovarian 17 alpha-hydroxylase activity by a direct noncompetitive mechanism. Endocrinology. 1996;137(1):166–74.PubMedCrossRef
82.
Fried G, Wramsby H, Tally M. Transforming growth factor-beta1, insulin-like growth factors, and insulin-like growth factor binding proteins in ovarian follicular fluid are differentially regulated by the type of ovarian hyperstimulation used for in vitro fertilization. Fertil Steril. 1998;70(1):129–34.PubMedCrossRef
83.
Channing CP, Kammerman S. Binding of gonadotropins to ovarian cells. Biol Reprod. 1974;10(2):179–98.PubMedCrossRef
84.
Ubaldi F, Albano C, Peukert M, Riethmuller-Winzen H, Camus M, Smitz J, et al. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles. Hum Reprod. 1996;11(7):1405–7.PubMedCrossRef
85.
86.
87.
Rashtian J, Zhang J. Luteal-phase ovarian stimulation increases the number of mature oocytes in older women with severe diminished ovarian reserve. Syst Biol Reprod Med. 2018;64(3):216–9.PubMedCrossRef
88.
Ding N, Chang J, Jian Q, Liang X, Liang Z, Wang F. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2016;32(11):866–71.PubMedCrossRef
89.
Li Y, Yang W, Chen X, Li L, Zhang Q, Yang D. Comparison between follicular stimulation and luteal stimulation protocols with clomiphene and HMG in women with poor ovarian response. Gynecol Endocrinol. 2016;32(1):74–7.PubMedCrossRef
90.
Eldar-Geva T, Margalioth EJ, Brooks B, Algur N, Zylber-Haran E, Diamant YZ. The origin of serum progesterone during the follicular phase of menotropin-stimulated cycles. Hum Reprod. 1998;13(1):9–14.PubMedCrossRef
91.
Strott CA, Yoshimi T, Ross GT, Lipsett MB. Ovarian physiology: relationship between plasma LH and steroidogenesis by the follicle and corpus luteum; effect of HCG. J Clin Endocrinol Metab. 1969;29(9):1157–67.PubMedCrossRef
92.
Judd S, Terry A, Petrucco M, White G. The source of pulsatile secretion of progesterone during the human follicular phase. J Clin Endocrinol Metab. 1992;74(2):299–305.PubMed
93.
De Geyter C, De Geyter M, Huber PR, Nieschlag E, Holzgreve W. Progesterone serum levels during the follicular phase of the menstrual cycle originate from the crosstalk between the ovaries and the adrenal cortex. Hum Reprod. 2002;17(4):933–9.PubMedCrossRef
94.
Requena A, Cruz M, Bosch E, Meseguer M, Garcia-Velasco JA. High progesterone levels in women with high ovarian response do not affect clinical outcomes: a retrospective cohort study. Reprod Biol Endocrinol. 2014;12(69):1477–7827.
95.
96.
Bu Z, Zhao F, Wang K, Guo Y, Su Y, Zhai J, et al. Serum progesterone elevation adversely affects cumulative live birth rate in different ovarian responders during in vitro fertilization and embryo transfer: a large retrospective study. PLoS ONE. 2014;9(6)PubMedPubMedCentralCrossRef
97.
98.
99.
Cai Q, Wan F, Appleby D, Hu L, Zhang H. Quality of embryos transferred and progesterone levels are the most important predictors of live birth after fresh embryo transfer: a retrospective cohort study. J Assist Reprod Genet. 2014;31(2):185–94.PubMedCrossRef
100.
Levy MJ, Smotrich DB, Widra EA, Sagoskin AW, Murray DL, Hall JL. The predictive value of serum progesterone and 17-OH progesterone levels on in vitro fertilization outcome. J Assist Reprod Genet. 1995;12(3):161–6.PubMedCrossRef
101.
Randall GW, Gantt PA, Gantt D, Kirk MJ, Romines N. Elevated serum progesterone values at the time of ovulation induction in luteal leuprolide acetate-down-regulated GIFT cycles are associated with decreased clinical pregnancy rates. J Assist Reprod Genet. 1996;13(6):459–63.PubMedCrossRef
102.
Lindheim SR, Cohen MA, Chang PL, Sauer MV. Serum progesterone before and after human chorionic gonadotropin injection depends on the estradiol response to ovarian hyperstimulation during in vitro fertilization-embryo transfer cycles. J Assist Reprod Genet. 1999;16(5):242–6.PubMedPubMedCentralCrossRef
103.
Silverberg KM, Martin M, Olive DL, Burns WN, Schenken RS. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration in in vitro fertilization cycles do not adversely affect embryo quality. Fertil Steril. 1994;61(3):508–13.PubMedCrossRef
104.
Fanchin R, Righini C, Olivennes F, Ferreira AL, de Ziegler D, Frydman R. Consequences of premature progesterone elevation on the outcome of in vitro fertilization: insights into a controversy. Fertil Steril. 1997;68(5):799–805.PubMedCrossRef
105.
106.
Hofmann GE, Khoury J, Johnson CA, Thie J, Scott RT Jr. Premature luteinization during controlled ovarian hyperstimulation for in vitro fertilization-embryo transfer has no impact on pregnancy outcome. Fertil Steril. 1996;66(6):980–6.PubMedCrossRef
107.
Moffitt DV, Queenan JT Jr, Shaw R, Muasher SJ. Progesterone levels on the day of human chorionic gonadotropin do not predict pregnancy outcome from the transfer of fresh or cryopreserved embryos from the same cohort. Fertil Steril. 1997;67(2):296–301.PubMedCrossRef
108.
Abuzeid MI, Sasy MA. Elevated progesterone levels in the late follicular phase do not predict success of in vitro fertilization-embryo transfer. Fertil Steril. 1996;65(5):981–5.PubMedCrossRef
109.
Urman B, Alatas C, Aksoy S, Mercan R, Isiklar A, Balaban B. Elevated serum progesterone level on the day of human chorionic gonadotropin administration does not adversely affect implantation rates after intracytoplasmic sperm injection and embryo transfer. Fertil Steril. 1999;72(6):975–9.PubMedCrossRef
110.
Martinez F, Coroleu B, Clua E, Tur R, Buxaderas R, Parera N, et al. Serum progesterone concentrations on the day of HCG administration cannot predict pregnancy in assisted reproduction cycles. Reprod BioMed Online. 2004;8(2):183–90.PubMedCrossRef
111.
Azem F, Tal G, Lessing JB, Malcov M, Ben-Yosef D, Almog B, et al. Does high serum progesterone level on the day of human chorionic gonadotropin administration affect pregnancy rate after intracytoplasmic sperm injection and embryo transfer? Gynecol Endocrinol. 2008;24(7):368–72.PubMedCrossRef
112.
113.
114.
Sims JA, Seltman HJ, Muasher SJ. Early follicular rise of serum progesterone concentration in response to a flare-up effect of gonadotrophin-releasing hormone agonist impairs follicular recruitment for in-vitro fertilization. Hum Reprod. 1994;9(2):235–40.PubMedCrossRef
115.
Huang CC, Lien YR, Chen HF, Chen MJ, Shieh CJ, Yao YL, et al. The duration of pre-ovulatory serum progesterone elevation before hCG administration affects the outcome of IVF/ICSI cycles. Hum Reprod. 2012;27(7):2036–45.PubMedCrossRef
116.
Mutlu MF, Erdem M, Erdem A, Mutlu I, Guler I, Demirdag E. The impact of premature progesterone rise on the outcome of intrauterine insemination cycles with controlled ovarian hyperstimulation in unexplained infertility. Eur J Obstet Gynecol Reprod Biol. 2016;203:44–8.PubMedCrossRef
117.
Requena A, Cruz M, Pacheco A, Garcia-Velasco JA. Ongoing pregnancy rates in intrauterine insemination are affected by late follicular-phase progesterone levels. Fertil Steril. 2015;104(4):879–83.PubMedCrossRef
118.
Doldi N, Marsiglio E, Destefani A, Gessi A, Merati G, Ferrari A. Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome. Hum Reprod. 1999;14(3):601–5.PubMedCrossRef
119.
Li R, Qiao J, Wang L, Zhen X, Lu Y. Serum progesterone concentration on day of HCG administration and IVF outcome. Reprod BioMed Online. 2008;16(5):627–31.PubMedCrossRef
120.
Ghaseminejad A, Rezaee Z, Forootan M, Hosseinipoor T, Forghani F, Nikuei P. Effect of predictive value of progesterone level on the day of HCG injection for IVF success in women with infertility due to tubal factor or polycystic ovarian syndrome referred to the women hospital, Tehran, 2009. Iran J Reprod Med. 2012;10(4):349–54.PubMedPubMedCentral
121.
Rezaee Z, Ghaseminejad A, Forootan M, Hosseinipoor T, Forghani F. Assessment of serum progesterone level on the day of hCG injection in infertile polycystic ovarian syndrome patients referred to Women's Hospital, Tehran, 2009. Int J Fertil Steril. 2012;5(4):231–4.PubMedPubMedCentral
122.
Saharkhiz N, Salehpour S, Tavasoli M, Aghighi A. Premature progesterone rise at human chorionic gonadotropin triggering day has no correlation with intracytoplasmic sperm injection outcome. Iran J Reprod Med. 2015;13(2):79–84.PubMedPubMedCentral
123.
Li R, Qiao J, Wang L, Li L, Zhen X, Liu P, et al. MicroRNA array and microarray evaluation of endometrial receptivity in patients with high serum progesterone levels on the day of hCG administration. Reprod Biol Endocrinol. 2011;9(29):1477–7827.
124.
Acet M, Aktun LH, Basaranoglu S, Yorgunlar B, Acet T, Deregozu A. Premature progesterone elevation does not affect pregnancy outcome in high-responder patients undergoing short-interval coasting in IVF cycles. Med Sci Monit Basic Res. 2015;21:247–52.PubMedPubMedCentralCrossRef
125.
Papaleo E, Corti L, Vanni VS, Pagliardini L, Ottolina J, De Michele F, et al. Basal progesterone level as the main determinant of progesterone elevation on the day of hCG triggering in controlled ovarian stimulation cycles. Arch Gynecol Obstet. 2014;290(1):169–76.PubMed
126.
Groenewoud ER, Macklon NS, Cohlen BJ. The effect of elevated progesterone levels before HCG triggering in modified natural cycle frozen-thawed embryo transfer cycles. Reprod BioMed Online. 2017;34(5):546–54.PubMedCrossRef
127.
Miller KF, Behnke EJ, Arciaga RL, Goldberg JM, Chin NW, Awadalla SG. The significance of elevated progesterone at the time of administration of human chorionic gonadotropin may be related to luteal support. J Assist Reprod Genet. 1996;13(9):698–701.PubMedCrossRef
128.
129.
Corti L, Papaleo E, Pagliardini L, Rabellotti E, Molgora M, La Marca A, et al. Fresh blastocyst transfer as a clinical approach to overcome the detrimental effect of progesterone elevation at hCG triggering: a strategy in the context of the Italian law. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):73–7.CrossRefPubMed
130.
Huang B, Li Z, Zhu L, Hu D, Liu Q, Zhu G, et al. Progesterone elevation on the day of HCG administration may affect rescue ICSI. Reprod BioMed Online. 2014;29(1):88–93.PubMedCrossRef
131.
Santos-Ribeiro S, Polyzos NP, Haentjens P, Smitz J, Camus M, Tournaye H, et al. Live birth rates after IVF are reduced by both low and high progesterone levels on the day of human chorionic gonadotrophin administration. Hum Reprod. 2014;29(8):1698–705.PubMedCrossRef
132.
133.
Venetis CA, Kolibianakis EM, Bosdou JK, Lainas GT, Sfontouris IA, Tarlatzis BC, et al. Estimating the net effect of progesterone elevation on the day of hCG on live birth rates after IVF: a cohort analysis of 3296 IVF cycles. Hum Reprod. 2015;30(3):684–91.PubMedCrossRef
134.
Healy MW, Yamasaki M, Patounakis G, Richter KS, Devine K, DeCherney AH, et al. The slow growing embryo and premature progesterone elevation: compounding factors for embryo-endometrial asynchrony. Hum Reprod. 2017;32(2):362–7.PubMedCrossRef
135.
Katsoff B, Check JH, Wilson C, Choe JK. Effect of serum progesterone level on the day of human chorionic gonadotropin injection on outcome following in vitro fertilization-embryo transfer in women using gonadotropin releasing hormone antagonists. Clin Exp Obstet Gynecol. 2011;38(4):322–3.PubMed
136.
Ochsenkuhn R, Arzberger A, von Schonfeldt V, Gallwas J, Rogenhofer N, Crispin A, et al. Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted reproductive technology: a retrospective study with 2,555 fresh embryo transfers. Fertil Steril. 2012;98(2):347–54.PubMedCrossRef
137.
Connell MT, Patounakis G, Healy MW, DeCherney AH, Devine K, Widra E, et al. Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Fertil Steril. 2016;106(3):584–9.PubMedCrossRef
138.
Younis JS, Matilsky M, Radin O, Ben-Ami M. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist. Fertil Steril. 2001;76(2):294–9.PubMedCrossRef
139.
Ou YC, Lan KC, Chang SY, Kung FT, Huang FJ. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone. Taiwan J Obstet Gynecol. 2008;47(2):168–74.PubMedCrossRef
140.
Lai T-H, Lee F-K, Lin T-K, Horng S-G, Chen S-C, Chen Y-H, et al. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin releasing hormone agonist protocol. Fertil Steril. 2009;92(2):508–14. https://​doi.​org/​10.​1016/​j.​fertnstert.​2008.​06.​036.CrossRefPubMed
141.
Cetinkaya ES, Berker B, Aytac R, Atabekoglu C, Sonmezer M, Ozmen B. The value of the progesterone-to-estradiol ratio on the day of hCG administration in predicting ongoing pregnancy and live birth rates in normoresponders undergoing GnRH antagonist cycles. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):452–7.PubMedCrossRef
142.
Aflatoonian A, Davar R, Hojjat F. Elevated serum progesterone/ MII oocyte ratio on the day of human chorionic gonadotropin administration can predict impaired endometrial receptivity. Iran J Reprod Med. 2014;12(6):427–34.PubMedPubMedCentral
143.
144.
Younis JS, Matilsky M, Radin O, Ben-Ami M. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist. Fertil Steril. 2008;76(2):294–9. https://​doi.​org/​10.​1016/​s0015-0282(01)01918-5.CrossRef
145.
Singh N, Kaur SD, Malik N, Malhotra N, Vanamail P. Do increased levels of progesterone and progesterone/estradiol ratio on the day of human chorionic gonadotropin affects pregnancy outcome in long agonist protocol in fresh in vitro fertilization/intracytoplasmic sperm injection cycles? J Hum Reprod Sci. 2015;8(2):80–5.PubMedPubMedCentralCrossRef
146.
Elgindy EA. Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy. Fertil Steril. 2011;95(5):1639–44.PubMedCrossRef
147.
148.
Keltz MD, Stein DE, Berin I, Skorupski J. Elevated progesterone-to-estradiol ratio versus serum progesterone alone for predicting poor cycle outcome with in vitro fertilization. J Reprod Med. 2012;57(1–2):9–12.PubMed
149.
Lee FK, Lai TH, Lin TK, Horng SG, Chen SC. Relationship of progesterone/estradiol ratio on day of hCG administration and pregnancy outcomes in high responders undergoing in vitro fertilization. Fertil Steril. 2009;92(4):1284–9.PubMedCrossRef
150.
Hamori M, Stuckensen JA, Rumpf D, Kniewald T, Kniewald A, Kurz CS. Premature luteinization of follicles during ovarian stimulation for in-vitro fertilization. Hum Reprod. 1987;2(8):639–43.PubMedCrossRef
151.
Dai W, Bu ZQ, Wang LL, Sun YP. The relationship between the changes in the level of progesterone and the outcome of in vitro fertilization-embryo transfer. Syst Biol Reprod Med. 2015;61(6):388–97.PubMedCrossRef
152.
153.
154.
155.
Patton PE, Lim JY, Hickok LR, Kettel LM, Larson JM, Pau KY. Precision of progesterone measurements with the use of automated immunoassay analyzers and the impact on clinical decisions for in vitro fertilization. Fertil Steril. 2014;101(6):1629–36.PubMedCrossRef
156.
Liu JH, Yen SS. Induction of midcycle gonadotropin surge by ovarian steroids in women: a critical evaluation. J Clin Endocrinol Metab. 1983;57(4):797–802.PubMedCrossRef
157.
Permezel JM, Lenton EA, Roberts I, Cooke ID. Acute effects of progesterone and the antiprogestin RU 486 on gonadotropin secretion in the follicular phase of the menstrual cycle. J Clin Endocrinol Metab. 1989;68(5):960–5.PubMedCrossRef
158.
Faulisi S, Reschini M, Borroni R, Paffoni A, Busnelli A, Somigliana E. Clinical value of basal serum progesterone prior to initiate ovarian hyper-stimulation with GnRH antagonists: a retrospective cohort study. Gynecol Obstet Investig. 2017;82(2):175–80.CrossRef
159.
Tang Y, Gong F, Lin G, Lu G. Early follicular progesterone concentrations and in vitro fertilization pregnancy outcomes. Fertil Steril. 2007;87(4):991–4.PubMedCrossRef
160.
Burns WN, Witz CA, Klein NA, Silverberg KM, Schenken RS. Serum progesterone concentrations on the day after human chorionic gonadotropin administration and progesterone/oocyte ratios predict in vitro fertilization/embryo transfer outcome. J Assist Reprod Genet. 1994;11(1):17–23.PubMedCrossRef
161.
Nayak S, Ochalski ME, Fu B, Wakim KM, Chu TJ, Dong X, et al. Progesterone level at oocyte retrieval predicts in vitro fertilization success in a short-antagonist protocol: a prospective cohort study. Fertil Steril. 2014;101(3):676–82.PubMedCrossRef
162.
Ozkaya E, Kutlu T, Abide Yayla C, Kayatas Eser S, Sanverdi I, Devranoglu B. Area under the curve of temporal estrogen and progesterone measurements during assisted reproductive technology: which hormone is the main determinant of cycle outcome? J Obstet Gynaecol Res. 2017;24(10):13492.
163.
164.
Lee VC, Li RH, Chai J, Yeung TW, Yeung WS, Ho PC, et al. Effect of preovulatory progesterone elevation and duration of progesterone elevation on the pregnancy rate of frozen-thawed embryo transfer in natural cycles. Fertil Steril. 2014;101(5):1288–93.PubMedCrossRef
165.
Kyrou D, Kolibianakis EM, Fatemi HM, Camus M, Tournaye H, Tarlatzis BC, et al. High exposure to progesterone between the end of menstruation and the day of triggering final oocyte maturation is associated with a decreased probability of pregnancy in patients treated by in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril. 2011;96(4):884–8. https://​doi.​org/​10.​1016/​j.​fertnstert.​2011.​07.​1101.CrossRefPubMed
166.
Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. Curr Pharm Biotechnol. 2012;13(3):464–70.PubMedCrossRef
167.
168.
Huang PC, Chen MJ, Guu HF, Yi YC, Ho JY, Chen YF, et al. Effect of premature serum progesterone rise on embryo transfer outcomes and the role of blastocyst culture and transfer in assisted reproductive technology cycles with premature progesterone rise. Taiwan J Obstet Gynecol. 2015;54(6):641–6.PubMedCrossRef
169.
Wei M, Zhang XM, Gu FL, Lv F, Ji YR, Liu KF, et al. The impact of LH, E2, and P level of HCG administration day on outcomes of in vitro fertilization in controlled ovarian hyperstimulation. Clin Exp Obstet Gynecol. 2015;42(3):361–6.PubMed
170.
Martinez F, Rodriguez I, Devesa M, Buxaderas R, Gomez MJ, Coroleu B. Should progesterone on the human chorionic gonadotropin day still be measured? Fertil Steril. 2016;105(1):86–92.PubMedCrossRef
171.
172.
Kilicdag EB, Haydardedeoglu B, Cok T, Hacivelioglu SO, Bagis T. Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles. Arch Gynecol Obstet. 2010;281(4):747–52.PubMedCrossRef
173.
Fanchin R, Hourvitz A, Olivennes F, Taieb J, Hazout A, Frydman R. Premature progesterone elevation spares blastulation but not pregnancy rates in in vitro fertilization with coculture. Fertil Steril. 1997;68(4):648–52.PubMedCrossRef
174.
Givens CR, Schriock ED, Dandekar PV, Martin MC. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cycles. Fertil Steril. 1994;62(5):1011–7.PubMedCrossRef
175.
Huang B, Ren X, Wu L, Zhu L, Xu B, Li Y, et al. Elevated progesterone levels on the day of oocyte maturation may affect top quality embryo IVF cycles. PLoS ONE. 2016;11(1)PubMedPubMedCentralCrossRef
176.
Kofinas JD, Mehr H, Ganguly N, Biley Y, Bochkovsky S, McCulloh D, et al. Is it the egg or the endometrium? Elevated progesterone on day of trigger is not associated with embryo ploidy nor decreased success rates in subsequent embryo transfer cycles. J Assist Reprod Genet. 2016;33(9):1169–74.PubMedPubMedCentralCrossRef
177.
Urrego R, Herrera-Puerta E, Chavarria NA, Camargo O, Wrenzycki C, Rodriguez-Osorio N. Follicular progesterone concentrations and messenger RNA expression of MATER and OCT-4 in immature bovine oocytes as predictors of developmental competence. Theriogenology. 2015;83(7):1179–87.PubMedCrossRef
178.
O'Shea LC, Mehta J, Lonergan P, Hensey C, Fair T. Developmental competence in oocytes and cumulus cells: candidate genes and networks. Syst Biol Reprod Med. 2012;58(2):88–101.PubMedCrossRef
179.
Check JH, Wilson C, Choe JK, Amui J, Brasile D. Evidence that high serum progesterone (P) levels on day of human chorionic gonadotropin (hCG) injection have no adverse effect on the embryo itself as determined by pregnancy outcome following embryo transfer using donated eggs. Clin Exp Obstet Gynecol. 2010;37(3):179–80.PubMed
180.
Liu L, Huang J, Li TC, Hong XT, Laird S, Dai YD, et al. The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium. J Reprod Immunol. 2017;121:17–25.PubMedCrossRef
181.
Huang R, Fang C, Xu S, Yi Y, Liang X. Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: an analysis of 2,566 cycles. Fertil Steril. 2012;98(3):664–70.PubMedCrossRef
182.
Lahoud R, Kwik M, Ryan J, Al-Jefout M, Foley J, Illingworth P. Elevated progesterone in GnRH agonist down regulated in vitro fertilisation (IVFICSI) cycles reduces live birth rates but not embryo quality. Arch Gynecol Obstet. 2012;285(2):535–40.PubMedCrossRef
183.
Lambalk CB, Leader A, Olivennes F, Fluker MR, Andersen AN, Ingerslev J, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial*. Hum Reprod. 2006;21(3):632–9. https://​doi.​org/​10.​1093/​humrep/​dei386.CrossRefPubMed
184.
185.
186.
187.
188.
189.
Al-Azemi M, Kyrou D, Kolibianakis EM, Humaidan P, Van Vaerenbergh I, Devroey P, et al. Elevated progesterone during ovarian stimulation for IVF. Reprod BioMed Online. 2012;24(4):381–8.PubMedCrossRef
190.
191.
192.
Bedaiwy MA, Abdelaleem MA, Hussein M, Mousa N, Brunengraber LN, Casper RF. Hormonal, follicular and endometrial dynamics in letrozole-treated versus natural cycles in patients undergoing controlled ovarian stimulation. Reproduct Biol Endocrinol: RB&E. 2011;9:83. https://​doi.​org/​10.​1186/​1477-7827-9-83.CrossRef
193.
Bedaiwy MA, Shokry M, Mousa N, Claessens A, Esfandiari N, Gotleib L, et al. Letrozole co-treatment in infertile women 40 years old and older receiving controlled ovarian stimulation and intrauterine insemination. Fertil Steril. 2009;91(6):2501–7.PubMedCrossRef
194.
Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;24(2)
195.
196.
Escudero EL, Boerrigter PJ, Bennink HJTC, Epifanio R, Horcajadas JA, Olivennes F, et al. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian Hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2005;90(4):2081–8. https://​doi.​org/​10.​1210/​jc.​2004-1160.CrossRefPubMed
197.
Barash A, Shoham Z, Lunenfeld B, Segal I, Insler V, Borenstein R. Can premature luteinization in superovulation protocols be prevented by aspiration of an ill-timed leading follicle? Fertil Steril. 1990;53(5):865–9.PubMedCrossRef
198.
Jones HW Jr, Acosta AA, Andrews MC, Garcia JE, Jones GS, Mayer J, et al. Three years of in vitro fertilization at Norfolk. Fertil Steril. 1984;42(6):826–34.PubMedCrossRef
199.
200.
201.
Vanni VS, Viganò P, Quaranta L, Pagliardini L, Giardina P, Molgora M, et al. Are extremely high progesterone levels still an issue in IVF? J Endocrinol Investig. 2017;40(1):69–75.CrossRef
202.
Kolibianakis EM, Bourgain C, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, et al. Prolongation of follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Hum Reprod. 2005;20(9):2453–6.PubMedCrossRef
203.
Polotsky AJ, Daif JL, Jindal S, Lieman HJ, Santoro N, Pal L. Serum progesterone on the day of human chorionic gonadotropin administration predicts clinical pregnancy of sibling frozen embryos. Fertil Steril. 2009;92(6):1880–5.PubMedCrossRef
204.
205.
Healy MW, Patounakis G, Connell MT, Devine K, DeCherney AH, Levy MJ, et al. Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles? Fertil Steril. 2016;105(1):93–9.PubMedCrossRef
206.
Yang S, Pang T, Li R, Yang R, Zhen X, Chen X, et al. The individualized choice of embryo transfer timing for patients with elevated serum progesterone level on the HCG day in IVF/ICSI cycles: a prospective randomized clinical study. Gynecol Endocrinol. 2015;31(5):355–8.PubMedCrossRef
207.
Metadata
Title
The curious case of premature luteinization
Authors
Apostolos Kaponis
Elpiniki Chronopoulou
George Decavalas
Publication date
01-10-2018
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 10/2018
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-018-1264-8

Other articles of this Issue 10/2018

Journal of Assisted Reproduction and Genetics 10/2018 Go to the issue

Letter to the Editor

Variations in the endometrial receptivity assay (ERA) may actually represent test error

REPRODUCTIVE PHYSIOLOGY AND DISEASE

Micro-RNAs involved in cellular proliferation have altered expression profiles in granulosa of young women with diminished ovarian reserve

REPRODUCTIVE PHYSIOLOGY AND DISEASE

Transcripts encoding free radical scavengers in human granulosa cells from primordial and primary ovarian follicles

Letter to Editor

Assisted reproduction techniques and prenatal diagnosis of Beckwith–Wiedemann spectrum presenting with omphalocele

Fertility Preservation

Fertility preservation in women with cancer: a national study about French oncologists awareness, experience, and feelings

Fertility Preservation

Antral follicle count recovery in women with menses after treatment with and without gonadotropin-releasing hormone agonist use during chemotherapy for breast cancer